Compare 8x8 Inc (EGHT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? 8x8 Inc trades at $2.2 (market cap $311.98M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 408.8× 8x8 Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EGHT | VRTX | |
|---|---|---|
Market Cap | $311.98M | $127.55B |
Volume | 1,639,086 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $2.76 | $557.96 |
52-Week Low | $1.59 | $407.37 |
Typical Hold Time | 16 Days | 120 Days |
Enterprise Value | $578.90M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.14, down 1.38% on the day. The stock exhibits a bullish technical signal with positive moving averages, while recent earnings have consistently beaten expectations. Revenue for 2025 was $715.07M, though the company reported a net loss of $27.21M. Positive news includes a 50% cost reduction for a major client using its platform and recent industry award recognition, highlighting operational strengths.
The outlook is mixed; analyst consensus is a Buy with a $19.77 price target, signaling significant upside potential. However, high debt levels and thin net margins pose risks. The projected return to profitability in 2026 is a key catalyst, but execution risks and competitive pressures in the cloud communications sector remain concerns for investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
